AS703569 Phase I in Patients With Solid Tumours

Study Overview
=================
Brief Summary
-----------------
This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.

Official Title
-----------------
A Phase I Multicenter, Open-Label, Dose Escalation Trial of AS703569 Given Orally to Subjects With Solid Tumours

Conditions
-----------------
Solid Tumors

Intervention / Treatment
-----------------
* Drug: AS703569
* Drug: AS703569
* Drug: AS703569


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histopathologically confirmed locally advanced or metastatic solid tumour that is either refractory after standard of care therapy for the disease or for which standard of care therapy is not reliably effective or has a cancer for which no standard therapy exists Age greater than or equal to 18 years Has read and understands the informed consent form and is willing and able to give informed consent, and subject authorization under Health Insurance Portability and Accountability Act (HIPAA). Fully understands requirements of the study and willing to comply with all study visits and assessments Subjects and their partners must be willing to avoid pregnancy during the study and until 1 month after the last study drug administration. Males with female partners of childbearing potential and female subjects of childbearing potential must therefore be willing to use adequate contraception such as, intra uterine device, diaphragm, or condom, for the duration of the study. For the purposes of this study, childbearing potential is defined as: All female subjects unless they are post- menopausal for at least two years, are surgically sterile or sexually inactive Negative serum pregnancy test at the screening visit for women of childbearing potential Exclusion Criteria: Bone marrow impairment as evidenced by Hb < 9.0 g/dl, ANC < 1.5x 109/L, platelets < 75 x 109/L. Subjects may be transfused. Renal impairment as evidenced by serum creatinine > 1.5 x ULN (upper limit of normal), and/or calculated creatinine clearance < 60 ml/min Liver function abnormality as defined by total bilirubin > 1.5 ULN, or AST or ALT > 2.5x ULN at screening; for subjects with liver involvement AST or ALT > 5x ULN at screening INR (blood coagulation) > 1.5 x ULN for subjects not on therapeutic doses of coumadin History of CNS metastases, unless subject has been previously treated for CNS metastases, is stable by CT scan without evidence of cerebral edema, and has no requirements for corticosteroids or anticonvulsants History of difficulty swallowing, malabsorption or other chronic gastro- intestinal disease or conditions that may hamper compliance and/or absorption of the tested product Eastern Cooperative Oncology Group Performance Status (ECOG PS) > 2 Known HIV, hepatitis C, or hepatitis B positivity Has received chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any other anticancer therapy or surgical intervention within 28 Days of Day 1 of study drug treatment (6 weeks for nitrosureas or mitomycin C), and must have fully recovered Has received extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation Has received any investigational agent within 28 days of Day 1 Has history of any other significant medical disease or intervention including major gastric or small bowel surgery or has a psychiatric condition that might impair the subjects well-being or preclude full participation in the study Is a pregnant or nursing female

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Regimen 1 | Drug: AS703569<br>* Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle<br>* Other names: Aurora kinase inhibitor;|
| Active Comparator: 2<br>Regimen 2 | Drug: AS703569<br>* Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle<br>* Other names: Aurora kinase inhibitor;|
| Active Comparator: 3<br>Regimen 3 | Drug: AS703569<br>* Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle<br>* Other names: Aurora kinase inhibitor;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number and proportion of subjects experiencing: at least a Dose-Limiting Toxicity (DLT) in each cohort during the first cycle. |  | Undefined | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma and urine PK parameters of AS703569, genetic markers and potential markers of clinical and biological response. |  | Undefined | 
| Number and proportion of subjects with Progressive Disease as assessed at the end of every other cycle. |  | Undefined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oncology. All solid Tumour disease.